A new study published by EClinicalMedicine provides an in-depth look at how patients with post-traumatic stress disorder experience psilocybin-assisted treatment, offering qualitative insight into how the therapy differs from standard PTSD treatments and how participants engage with trauma during dosing sessions.
The research was conducted by scientists from King’s College London, University of Bath, Icahn School of Medicine at Mount Sinai and James J. Peters Bronx Veterans Affairs Hospital. It was embedded within an open-label phase 2 clinical trial evaluating the safety and tolerability of a single administration of COMP360 psilocybin in adults diagnosed with PTSD.
The qualitative study involved 21 participants who met DSM-5 criteria for PTSD stemming from traumatic events experienced in adulthood. Participants were enrolled between June 2022 and February 2024 at three sites in the U.S. and the U.K. All participants completed standardized preparation sessions, a monitored psilocybin dosing session, and follow-up integration visits. Researchers conducted semi-structured interviews before treatment, the day after dosing, and again 12 weeks later.
Analysis of the interviews identified four core themes, including the importance of psychological safety and trust, the experiential nature of psilocybin treatment, how trauma-related material emerged during sessions, and how participants compared psilocybin with prior therapies. Participants reported that, unlike conventional treatments that often require direct and repeated confrontation with traumatic memories, psilocybin allowed for more indirect engagement with trauma through emotional, bodily, and self-transcendent experiences.
Researchers concluded that psilocybin, when paired with structured preparation and therapeutic support, may represent a meaningful treatment option for PTSD. They emphasized the need for larger, controlled trials using mixed research methods to better understand how symptom changes, functional outcomes, and patient experiences interact over time.
More articles from The Marijuana Herald:
